Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 13,075 matching trials from the live ClinicalTrials.gov search.

Filters: Atlanta, Georgia Clear all

Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions: Percutaneous Coronary Intervention (PCI); Procedure
Lead sponsor: University of British Columbia; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 55
States / cities: Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin, glimepiride, linagliptin placebo, glimepiride placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 6,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 177
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more

Conditions: Migraine
Interventions: EVO756, Dose 1, EVO756, Dose 2, Placebo; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Chandler, Arizona • Buena Park, California • Fresno, California + 31 more

Conditions: Chronic Heart Failure
Interventions: HeartWare® VAS (HVAD), Control LVAD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Myasthenia Gravis
Interventions: thymectomy plus prednisone, prednisone alone; Procedure · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Solid and Hematological Malignancies
Interventions: Not listed
Lead sponsor: Adaptimmune; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 9,122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 25
States / cities: Duarte, California • Stanford, California • Boca Raton, Florida + 20 more

Conditions: Lymphoma
Interventions: HMPL-689; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 10
States / cities: Anaheim, California • Oxnard, California • Atlanta, Georgia + 6 more

Conditions: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna, Isatuximab; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin, Placebo; Drug · Other
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 36
States / cities: Birmingham, Alabama • Rogers, Arkansas • Garden Grove, California + 31 more

Conditions: Asthma
Interventions: Tezepelumab, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 30
States / cities: Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: Lumateperone high dose, Lumateperone low dose, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Little Rock, Arkansas • Sacramento, California • Sherman Oaks, California + 32 more

Conditions: Hidradenitis Suppurativa
Interventions: Ruxolitinib Cream, Vehicle Cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 580 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 59
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 51 more

Conditions: Allergy, Peanut
Interventions: DBV712, Placebo; Drug · Other
Lead sponsor: DBV Technologies; Industry
Eligibility: 4 Years to 7 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Multiple Myeloma
Interventions: IV busulfan, bortezomib, Autologous Hematopoietic Stem Cell Transplant (HSCT); Drug · Procedure
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Tucson, Arizona • Atlanta, Georgia • Maywood, Illinois + 7 more

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
Interventions: FOR46; Drug
Lead sponsor: Fortis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 4 more

Conditions: Sickle Cell Disease
Interventions: Arginine, Arginine (Loading), Arginine (Continuous); Drug
Lead sponsor: Emory University; Other
Eligibility: 7 Years to 21 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions: Lumateperone; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 59
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions: EndoTAG-1, Gemcitabine; Drug
Lead sponsor: SynCore Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 16
States / cities: Corona, California • Atlanta, Georgia • Columbus, Georgia + 12 more

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
Interventions: navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy; Biological
Lead sponsor: OncXerna Theraputics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more

Conditions: Adolescent Idiopathic Scoliosis
Interventions: Brace, Observation; Device · Other
Lead sponsor: Stuart L. Weinstein, MD; Other
Eligibility: 10 Years to 15 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 22
States / cities: Madera, California • Sacramento, California • San Diego, California + 18 more

Conditions: Mild Traumatic Brain Injury
Interventions: TEaM Intervention, Standard of Care; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 5 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: HIV Prevention Trials Network; Network
Eligibility: 18 Years and older
Enrollment: 2,099 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide; Drug · Procedure · Radiation + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years to 70 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 418
States / cities: Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more

Conditions: MPN (Myeloproliferative Neoplasms)
Interventions: Ruxolitinib, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 88
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Baldwin Park, California + 85 more

Search by objective public record fields.

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Study of EVO756 in Adults With Migraine

A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination

Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST)

TBI Evaluation and Management (TEaM)

The Women's HIV SeroIncidence Study (ISIS)

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial